DXR Share Price Performance
US$9.45
0.65 (7.39%)
Price US$9.45
Share PriceUS$9.45
DXR Community Narratives
There are no narratives available yet.
Recent DXR News & Updates
No updates
Daxor Corporation Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 0.11
- Gross Margin
- 100.00%
- Net Profit Margin
- 448.01%
- Debt/Equity Ratio
- 2.0%
Daxor Corporation Competitors
About DXR
- Founded
- 1971
- Employees
- n/a
- CEO
- WebsiteView website
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.
U.S. Market Performance
- 7 Days: -2.7%
- 3 Months: 11.4%
- 1 Year: 20.5%
- Year to Date: 5.9%
Over the last 7 days, the market has dropped 2.7%, driven by a pullback of 2.4% in the Information Technology sector. In contrast to the last week, the market is actually up 20% over the past year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading